Cantor Fitzgerald reiterated their overweight rating on shares of Invivyd (NASDAQ:IVVD – Free Report) in a research note published on Thursday morning, Marketbeat Ratings reports.
A number of other brokerages have also recently weighed in on IVVD. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered shares of Invivyd from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 24th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, August 18th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.
Check Out Our Latest Report on IVVD
Invivyd Price Performance
Invivyd (NASDAQ:IVVD – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Equities research analysts anticipate that Invivyd will post -0.51 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Jill Andersen sold 37,256 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $26,824.32. Following the transaction, the insider owned 314,480 shares of the company’s stock, valued at $226,425.60. This represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 228,024 shares of company stock valued at $176,540 over the last 90 days. Corporate insiders own 12.25% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC purchased a new position in shares of Invivyd in the 1st quarter valued at about $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in Invivyd during the fourth quarter worth approximately $27,000. DRW Securities LLC purchased a new stake in Invivyd during the fourth quarter worth approximately $27,000. ProShare Advisors LLC purchased a new stake in Invivyd during the fourth quarter worth approximately $30,000. Finally, State of Wyoming acquired a new position in Invivyd in the fourth quarter valued at approximately $30,000. 70.36% of the stock is owned by institutional investors and hedge funds.
Invivyd Company Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Read More
- Five stocks we like better than Invivyd
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
